Last updated: March 1, 2026
What is the Drug Identified by NDC 60505-1317?
NDC 60505-1317 corresponds to Yescarta (axicabtagene ciloleucel), a CAR T-cell therapy approved by the FDA for treating certain types of large B-cell lymphoma.
Market Overview
Yescarta is part of the immunotherapy segment targeting hematologic malignancies. Its primary indications include:
- Diffuse Large B-Cell Lymphoma (DLBCL), after at least two prior systemic therapies
- Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
- Fractional approval for treat relapsed or refractory follicular lymphoma
Market Size and Demand Drivers
Epidemiology
- DLBCL accounts for approximately 30% of non-Hodgkin lymphoma cases.
- Estimated annual incidence in the U.S. exceeds 20,000 cases.
- Refractory or relapsed cases amount to roughly 50% of patients diagnosed with DLBCL.
Market Drivers
- Growing prevalence of lymphoma among aging populations.
- Expanded FDA approvals for Yescarta in additional indications.
- Increased adoption owing to its potential for durable responses.
Competitors and Alternatives
| Product Name |
Indications |
Price (USD) |
Market Share (est.) |
| Tecartus (Kite Pharma) |
Mantle cell lymphoma/therapies for aggressive NHL |
$373,000 |
26% |
| Kymriah (Novartis) |
Acute lymphoblastic leukemia, DLBCL (adults) |
$475,000 |
32% |
Yescarta's market share has grown after approvals for additional indications, but remains competitive with Kymriah and Tecartus.
Price Projections and Market Trends
Current Pricing
- Wholesale acquisition cost (WAC): approximately $373,000 per treatment
- Actual paid prices often vary based on negotiations, discounts, and payer arrangements.
Future Price Trajectories
| Year |
Predicted Price Range (USD) |
Rationale |
| 2023 |
$350,000 - $375,000 |
Stable, given limited competition and high efficacy |
| 2024 |
$340,000 - $370,000 |
Slight pressure from biosimilar development, payer negotiations |
| 2025 |
$330,000 - $360,000 |
Potential reduction due to new entrants and market saturation |
Influencing Factors
- Manufacturing Costs: Advances in process efficiency could lower costs by 5–10% over next two years.
- Pricing Policies: Payer negotiation and value-based pricing could pressure prices downward.
- Regulatory Developments: Expanded indications or approval for biosimilars would impact pricing.
- Market Penetration: Increased adoption, especially in outpatient settings, might moderate price growth.
Revenue Projections
Based on an estimated annual treatment volume of 3,500–4,000 patients in the U.S.:
| Year |
Estimated Revenue (USD) |
Assumptions |
| 2023 |
$1.2 billion - $1.5 billion |
Stable prices, increased uptake |
| 2024 |
$1.1 billion - $1.4 billion |
Slight price decline, steady patient volume |
| 2025 |
$1 billion - $1.3 billion |
Continued market expansion with moderate price reduction |
Key Market Risks
- Potential safety concerns or post-market adverse events.
- Delays in reimbursement approvals.
- Competition from emerging CAR T-cell therapies or allogeneic options.
- Regulatory delays for newly approved indications.
Summary
Yescarta's market is characterized by high treatment costs, stable demand, and growing indications. Prices are likely to decline gradually due to market and regulatory pressures. Revenue projections remain strong, provided sales volumes increase in tandem with expanding indications.
Key Takeaways
- The approximate WAC price of Yescarta (NDC 60505-1317) remains around $373,000.
- Market demand is driven by the increasing incidence of large B-cell lymphomas and expanded indications.
- Prices are expected to decrease slowly over the next two years, influenced by payer negotiations and biosimilar competition.
- Revenue estimates suggest a potential for over $1 billion annually in the U.S. market by 2025.
- Market risks include safety concerns, regulatory hurdles, and competition from emerging therapies.
FAQs
-
What is the primary indication for Yescarta?
Treatment of relapsed or refractory large B-cell lymphoma after at least two prior therapies.
-
How does Yescarta compare in price to other CAR T therapies?
It is priced slightly lower than Kymriah ($475,000) but similar to Tecartus ($373,000).
-
Are biosimilars likely to impact Yescarta’s price?
Biosimilar development could lead to price reductions starting after 2025.
-
What factors most influence Yescarta's market share?
Expanded indications, regulatory approvals, and payer coverage policies.
-
What is the outlook for cost reductions in manufacturing?
Manufacturing efficiencies may lower costs by 5-10%, marginally impacting pricing.
Citations
[1] U.S. Food and Drug Administration. (2017). Yescarta (axicabtagene ciloleucel) prescribing information.
[2] IQVIA. (2022). Specialty Pharmacy Data on CAR T-cell therapies.
[3] Market Research Future. (2022). Global CAR T Cell Therapy Market Report.
[4] Centers for Disease Control and Prevention. (2022). Non-Hodgkin Lymphoma Statistics.
